Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA.
apolipoprotein
cardiovascular disease
lipids
risk
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
pmc-release:
01
08
2024
medline:
28
7
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
Apo CIII (apolipoprotein CIII) is an important regulator of triglyceride metabolism and was associated with cardiovascular risk in several cohorts. It is present in 4 major proteoforms, a native peptide (CIII Apo CIII proteoforms were measured by mass spectrometry immunoassay in baseline plasma samples of 5791 participants of Multi-Ethnic Study of Atherosclerosis, an observational community-based cohort. Standard plasma lipids were collected for up to 16 years and cardiovascular events (myocardial infarction, resuscitated cardiac arrest, or stroke) were adjudicated for up to 17 years. Apo CIII proteoform composition differed by age, sex, race and ethnicity, body mass index, and fasting glucose. Notably, CIII Our data indicate differences in clinical and demographic relationships of apo CIII proteoforms, and highlight the importance of apo CIII proteoform composition in predicting future lipid patterns and cardiovascular disease risk.
Sections du résumé
BACKGROUND
Apo CIII (apolipoprotein CIII) is an important regulator of triglyceride metabolism and was associated with cardiovascular risk in several cohorts. It is present in 4 major proteoforms, a native peptide (CIII
METHODS
Apo CIII proteoforms were measured by mass spectrometry immunoassay in baseline plasma samples of 5791 participants of Multi-Ethnic Study of Atherosclerosis, an observational community-based cohort. Standard plasma lipids were collected for up to 16 years and cardiovascular events (myocardial infarction, resuscitated cardiac arrest, or stroke) were adjudicated for up to 17 years.
RESULTS
Apo CIII proteoform composition differed by age, sex, race and ethnicity, body mass index, and fasting glucose. Notably, CIII
CONCLUSIONS
Our data indicate differences in clinical and demographic relationships of apo CIII proteoforms, and highlight the importance of apo CIII proteoform composition in predicting future lipid patterns and cardiovascular disease risk.
Identifiants
pubmed: 37317850
doi: 10.1161/ATVBAHA.123.319035
pmc: PMC10516344
mid: NIHMS1905899
doi:
Substances chimiques
Apolipoprotein C-III
0
Triglycerides
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1560-1571Subventions
Organisme : NHLBI NIH HHS
ID : 75N92020D00005
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95160
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95163
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001079
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95164
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95168
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95165
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95159
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00007
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201500003I
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000040
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00002
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201500003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00001
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95169
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95162
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00003
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95161
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001420
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00004
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL138969
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95167
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00006
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95166
Pays : United States
Références
Circulation. 2000 Oct 17;102(16):1886-92
pubmed: 11034934
J Lipid Res. 1981 Jul;22(5):800-10
pubmed: 7288286
J Lipid Res. 1985 May;26(5):556-65
pubmed: 4020294
Atherosclerosis. 2001 Sep;158(1):173-81
pubmed: 11500189
Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):239-45
pubmed: 19910636
Biochem Biophys Res Commun. 1972 Jan 31;46(2):375-82
pubmed: 5057882
Metabolism. 2004 Oct;53(10):1296-304
pubmed: 15375785
J Proteomics. 2022 Jan 16;251:104398
pubmed: 34688878
J Lipid Res. 1989 Nov;30(11):1781-7
pubmed: 2614277
Cell Metab. 2016 Aug 9;24(2):234-45
pubmed: 27508872
PLoS One. 2015 Dec 03;10(12):e0144138
pubmed: 26633899
J Lipid Res. 2016 May;57(5):894-905
pubmed: 26945091
J Lipid Res. 2010 Jan;51(1):150-61
pubmed: 19622837
Proteome Sci. 2016 Mar 25;14:7
pubmed: 27019641
J Clin Invest. 1985 Feb;75(2):384-90
pubmed: 3973011
Circulation. 1992 Sep;86(3):858-69
pubmed: 1516198
Biol Pharm Bull. 1993 May;16(5):448-52
pubmed: 8364489
J Biol Chem. 1997 Dec 12;272(50):31348-54
pubmed: 9395464
Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2145-2156
pubmed: 31390883
J Am Heart Assoc. 2018 Mar 14;7(6):
pubmed: 29540426
Circ Res. 2023 Feb 17;132(4):452-464
pubmed: 36691918
Science. 2008 Dec 12;322(5908):1702-5
pubmed: 19074352
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1013-1014
pubmed: 28539488
Thromb Res. 2007;119(1):73-8
pubmed: 16500696
PLoS One. 2014 Aug 01;9(8):e102265
pubmed: 25084356
J Am Coll Cardiol. 2017 Feb 21;69(7):789-800
pubmed: 28209220
Atherosclerosis. 2009 May;204(1):105-11
pubmed: 18834984
Arch Intern Med. 2008 Jun 23;168(12):1333-9
pubmed: 18574091
Circulation. 2006 Aug 15;114(7):681-7
pubmed: 16894036
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73
pubmed: 24222018
J Clin Lipidol. 2017 Jan - Feb;11(1):224-233.e2
pubmed: 28391889
J Clin Lipidol. 2021 Jan-Feb;15(1):235-242
pubmed: 33257283
N Engl J Med. 2015 Jul 30;373(5):438-47
pubmed: 26222559
J Lipid Res. 1999 Mar;40(3):543-55
pubmed: 10064743
Circulation. 2018 Mar 27;137(13):1364-1373
pubmed: 29162611
Am J Epidemiol. 2002 Nov 1;156(9):871-81
pubmed: 12397006
Circulation. 2018 Mar 27;137(13):1374-1390
pubmed: 29212895
N Engl J Med. 2014 Jul 3;371(1):32-41
pubmed: 24941082
Metabolism. 2017 Jul;72:75-82
pubmed: 28641786
Diabetes. 2009 Sep;58(9):2018-26
pubmed: 19502413
Circulation. 2011 Nov 8;124(19):2065-72
pubmed: 21986282
J Clin Invest. 1982 Apr;69(4):932-9
pubmed: 7076853
J Clin Invest. 2019 Jul 11;129(10):4165-4179
pubmed: 31295146
Clin Biochem. 2006 Jul;39(7):667-81
pubmed: 16624269
Circulation. 1994 Jul;90(1):42-9
pubmed: 8026027
J Lipid Res. 2006 Jun;47(6):1212-8
pubmed: 16495512
Circ Res. 2014 Jan 3;114(1):124-42
pubmed: 24385507
J Lipid Res. 2011 Jun;52(6):1067-1070
pubmed: 21421846
Circulation. 2008 Aug 12;118(7):731-42
pubmed: 18663085